Literature DB >> 27567741

Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.

Marc L Fleming1, Larry Driver2, Sujit S Sansgiry3, Susan M Abughosh3, Matthew Wanat4, Ruta V Sawant3, Erin Ferries3, Kathleen Reeve5, Knox H Todd6.   

Abstract

BACKGROUND: The U.S. Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products (HCPs) in an attempt to mitigate the prescription opioid epidemic. Many in the medical and pharmacy community expressed concerns of unintended consequences as a result of rescheduling.
OBJECTIVES: This study examined physicians' intentions to prescribe HCPs after rescheduling using the framework of the theory of reasoned action (TRA).
METHODS: A cover letter containing a link to the online questionnaire was sent to physicians of the Texas Medical Association who were likely to prescribe opioids. The questionnaire assessed physicians' intentions to prescribe HCPs after rescheduling. Predictor variables included attitude toward rescheduling, subjective norm toward HCP prescribing, and past prescribing behavior of schedule II prescriptions. All variables were measured on a 7-point, Likert-type scale. Intention to prescribe as a dependent variable was regressed over TRA variables and respondent characteristics.
RESULTS: A total of 1176 usable responses were obtained, yielding a response rate of 13.3%. Mean (M) age was 53.07 ± 11 and most respondents were male (70%) and Caucasian (75%). Physicians held a moderately positive intention to prescribe HCPs (M = 4.36 ± 2.08), held a moderately negative attitude towards rescheduling, M = 4.68 ± 1.51 (reverse coded). Subjective norm was moderately low, M = 3.06 ± 1.78, and past prescribing behavior M = 2.43 ± 1.21. The linear regression analysis indicated that attitude (β = 0.10; P = 0.006), subjective norm (β = 0.35; P < 0.0001) and past prescribing behavior (β = 0.59; P < 0.0001) were significant predictors of intention to prescribe HCPs after rescheduling.
CONCLUSIONS: TRA was shown to be a predictive model of physicians' intentions to prescribe HCPs after rescheduling. Overall, physicians held a moderately positive intention to prescribe HCPs. Past behavior concerning schedule II prescribing was found to be the most significant predictor of intention. Understanding the impact of federal rule changes on pain management care and patient satisfaction is necessary to determine whether this change has produced the intended consequences without harming patients in need of HCPs. Published by Elsevier Inc.

Entities:  

Keywords:  Hydrocodone; Opioid prescribing; Pain management; Prescription drug abuse; Rescheduling; Theory of reasoned action

Mesh:

Substances:

Year:  2016        PMID: 27567741     DOI: 10.1016/j.sapharm.2016.07.001

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  4 in total

1.  Analyzing Medical Guideline Dissemination Behaviors Using Culturally Infused Agent Based Modeling Framework.

Authors:  Eunice E Santos; John Korah; Suresh Subramanian; Vairavan Murugappan; Elbert S Huang; Neda Laiteerapong; Ali Cinar
Journal:  IEEE J Biomed Health Inform       Date:  2021-06-03       Impact factor: 5.772

2.  Perceived extrinsic barriers hinder community detection and management of mild cognitive impairment: a cross-sectional study of general practitioners in Shanghai, China.

Authors:  Yuan Lu; Chaojie Liu; Sally Fawkes; Zhaoxin Wang; Dehua Yu
Journal:  BMC Geriatr       Date:  2022-06-09       Impact factor: 4.070

3.  Quantification of Opioid Prescription Practice Changes Due to Hydrocodone Combination Product Rescheduling in an Academic Pain Clinic.

Authors:  John Ngo; David Parker; Mathew Meroney; Jasmine Mitchell; Oscar Veloz; Oliver Lee; Katherine A Cunningham; Denise Wilkes
Journal:  J Pain Res       Date:  2020-08-25       Impact factor: 3.133

4.  Intention to get naloxone among patients prescribed opioids for chronic pain.

Authors:  Yinan Huang; Ning Lyu; Shrey Gohil; Shweta Bapat; E James Essien; J Douglas Thornton
Journal:  Harm Reduct J       Date:  2022-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.